The Medicare drug pricing rule the Trump administration just finalized looks very different from the plan first put forward. What began as an ambitious push to bring American drug prices closer to those paid abroad has been trimmed down to a program that reaches only four companies, and the projected savings have shrunk by roughly 96 percent compared with the original proposal.

What the Final Rule Actually Does

The policy is called the Global Benchmark for Efficient Drug Pricing, or GLOBE. It is aimed at medicines that are given in a doctor’s office rather than picked up at a pharmacy, a category that makes up a significant share of what Medicare spends on drugs.

GLOBE is one of two mandatory pilot programs designed to push drugmakers toward lower Medicare prices. The goal is to move what Americans pay closer to what other wealthy nations pay. This approach is commonly known as most-favored nation pricing, or MFN.

The second pilot, known as GUARD, has not reached the finish line. It is still at the proposed stage, so its final shape remains uncertain.

Why the Reach Is So Narrow

On paper, GLOBE is mandatory. In practice, a large number of companies are excused from it.

The reason lies in a separate set of arrangements. The administration has struck voluntary agreements with drugmakers in which the companies offer MFN-level prices on medicines for people covered by Medicaid. Under the final rule, any company that signed one of those deals is exempt from GLOBE.

That exemption carves away much of the pool the program might otherwise have covered. When the dust settled, only four companies were left subject to the requirements.

Deals That Cut Both Ways

There is a clear tension here. The voluntary deals were presented as a way to deliver lower prices without a drawn-out fight. But by shielding the signers from the Medicare pilot, they appear to have weakened the very mechanism meant to apply broader pressure.

Think of it this way:

• The deals secure lower prices for Medicaid patients on certain drugs.
• Those same deals remove the signing companies from the Medicare pilot.
• The result is a Medicare program that touches far fewer products and generates far smaller savings.

Supporters of the voluntary approach may argue that negotiated agreements are faster and less contentious than mandatory rules. Critics are likely to counter that a program with so many exits built into it cannot deliver the sweeping change that was promised. Both views have some logic, and the numbers will shape which one gains traction.

Understanding the Savings Gap

The headline figure is hard to ignore. Compared with the original proposal, the final version is expected to save about 96 percent less. That is not a minor adjustment. It signals that the policy, as finalized, is a fraction of the original ambition.

For Medicare, the stakes are real. Drugs administered by clinicians can be extremely expensive, and the program’s spending on them has been a persistent concern for policymakers. A rule that reaches only a handful of manufacturers leaves most of that spending untouched.

What It Means for Patients and Taxpayers

For most people on Medicare, the immediate effect may be limited. If a drug comes from one of the four companies covered by the rule, there could be some benefit down the line. For medicines made by exempt companies, the GLOBE pilot changes little.

Taxpayers, who ultimately fund Medicare, should also temper expectations. The program was pitched as a way to rein in costs, but a 96 percent reduction in projected savings means far less relief for the federal budget than first suggested.

It is also worth remembering that the Medicaid agreements, while narrower in scope, do offer something concrete to the people they cover. The trade-off is that Medicare, a much larger program in terms of spending on these drugs, gets a lighter touch.

What Comes Next

Attention now turns to GUARD, the second pilot still awaiting a final decision. How it is written will reveal whether the administration plans to hold firm on mandatory pricing or continue to leave room for exemptions tied to company deals.

Several questions are worth watching:

• Will GUARD include similar carve-outs for companies with voluntary agreements?
• Will additional drugmakers sign deals to avoid mandatory requirements?
• How will the four companies covered by GLOBE respond to the rule?
• Will lawmakers or industry groups push for changes, or challenge the policy altogether?

The Bottom Line

The final GLOBE rule shows how a bold pricing idea can shrink once it runs into negotiation and compromise. The administration wanted Medicare to pay what other rich countries pay. What emerged is a limited pilot, covering four companies, with a fraction of the savings once projected.

Whether GUARD will follow the same path, or prove tougher, may determine how much of the original most-favored nation vision survives. For now, the gap between the promise and the final policy is wide, and patients, taxpayers, and the drug industry will all be watching to see if it narrows.